HealthLinx's ovarian diagnostic test takes aim at industry leader
Australian diagnostic company HealthLinx (ASX: HTX) has inked a collaborative deal with the Queensland Mater Health services, for HealthLinx's OvPlex™ ovarian cancer diagnostic. Nick Gatsios, managing...
View ArticleHealthLinx opens up key UK market for its OvPlex™ Ovarian Cancer Diagnostic
Victorian-based diagnostics company HealthLinx (ASX: HTX) has taken a big step forward forging a key second market for its ovarian cancer diagnostic OvPlex™ in the UK. The market responded to the...
View ArticleHealthlinx looking to become market leader with ovarian cancer diagnostic,...
HealthLinx Limited (ASX:HTX) has secured up to $750,000 for the company over the next 24 months, from execution of its Victorian Science Agenda (VSA) Investment Fund grant agreement today. Funding will...
View ArticleHealthLinx Ltd awarded Asia product of the Year for OvPlex™ ovarian cancer...
Industry leader Dr Steven Burrill of Burrill and Co. has been an advocate of new diagnostic technologies for the past 5 years.
View ArticleHealthLinx Limited secures samples for ovarian cancer study
HealthLinx (ASX: HTX) has secured over 400 of the first 450 samples required for its second and larger study of the OvPlexTM ovarian cancer diagnostic. The remainder have been sourced and are expected...
View ArticleHealthLinx Ltd launches ovarian cancer test into UK market
HealthLinx (ASX: HTX) has reported that UK distribution partner Intus Healthcare is targeting a significant share of the potential 750,000 annual ovarian cancer diagnostic tests undertaken in the UK...
View ArticleHealthLinx raises A$750,000 through private placement
HealthLinx (ASX: HTX) has reported that Stonebridge Securities Limited has successfully completed the placement of 7,500,000 ordinary fully paid shares at 10 cents each plus free attaching options, as...
View ArticleHealthLinx receives Australian patent for ovarian cancer test OvPlex™
HealthLinx (ASX: HTX) has received an Australian patent for the company’s ovarian cancer test OvPlex™, which examines a series of biomarkers from blood samples, and has been deemed a precursor to the...
View ArticleHealthLinx wins support of IgY Immunodepletion patent from European Patent...
HealthLinx (ASX: HTX) has reported that the European Patent Office (EPO) has dismissed Sigma Aldrich’s objection against the company’s IgY Immunodepletion patent. The directors of HealthLinx are...
View ArticleHealthLinx targets US$350m per annum prostate cancer market, expands research...
HealthLinx (ASX: HTX) will expand its collaboration with the Garvan Institute of Medical Research for the potential development of new markers to aid in prostate cancer prognosis on the back of...
View ArticleHealthLinx expands distribution of ovarian cancer test to Spain under new...
HealthLinx (ASX: HTX) has signed an agreement with Barcelona-based Oryzon Genomics for the distribution of the company’s ovarian cancer diagnostic, OvPlex™, in Spain, with an option to extend exclusive...
View ArticleHealthLinx ramps up push into U.S. ovarian cancer market with La Jolla Cove...
HealthLinx (ASX:HTX) will focus on accelerating the global expansion and development of its first-in-class ovarian cancer diagnostic test, OvPlex™, following the signing of a funding agreement with La...
View ArticleHealthLinx ahead of schedule for patient recruitment on positive trial...
HealthLinx (ASX: HTX) could have patient recruitment for its second multi-centre, multi-national trial of its ovarian cancer test, OvPlex™, finalised by the end of the March quarter 2012 due to...
View ArticleHealthLinx confirms potential of novel biomarker in predicting ovarian cancer...
HealthLinx (ASX: HTX) has validated a novel protein biomarker that can predict the clinical outcome in ovarian cancer patients as part of a large collaborative study assessing the potential prognostic...
View ArticleHealthLinx marches towards approval for ovarian cancer diagnostic in sixth...
HealthLinx (ASX: HTX) is a step closer to obtaining regulatory approvals for its first-in-class ovarian cancer diagnostic test, OvPlex™, in South Korea. The South Korean market for ovarian cancer...
View ArticleHealthLinx soon to begin sales of OvPlex™ in fast growing Indian market
HealthLinx’s (ASX: HTX) successful expansion of sales of its first-in-class ovarian cancer diagnostic test, OvPlex™, into the Singapore and Malaysian markets has prompted further expansion into other...
View ArticleHealthLinx a step closer to expanding ovarian cancer test sales to the South...
Nick Gatsios, managing director of HealthLinx, told Proactive Investors today while the positive results from a South Korean study of OvPlex™ are preliminary in nature, they demonstrate statistical...
View ArticleHealthLinx snares former Prima Biomed manager as GM for Australian operations
HealthLinx (ASX: HTX) has gained the experience of former business development and intellectual property manager for Prima BioMed Vanessa Waddell with her appointment as general manager for Australian...
View ArticleHealthLinx in pre open pending substantial asset sale announcement
HealthLinx (ASX: HTX) has been granted a trading halt this morning from the ASX pending the release of an announcement on a substantial asset sale.The halt will last until the earlier of an...
View ArticleHealthLinx to commercialise assets in the U.S. after deal with Mane Cancer...
The majority of HealthLinx’s assets, including its ovarian cancer diagnostic OvPlex™, have attracted a value of A$6.25 million with the proposed sale to Mane Cancer Diagnostics. The sale will allow...
View Article
